

Ontario Public Drug Programs

Drug Submission Status

Report for November 2015

Complete Streamlined Multiple-Source

Submissions for Future Formulary Listing

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for listing on the Ontario Drug Benefit Formulary. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be listed as benefits in a future Formulary update. Final listing status will be communicated when the Formulary update is published on the Ministry website and via an OPDP Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Actavis Pharma Company	Co Valacyclovir	Valtrex	valacyclovir HCl	500mg	FC tablet	02331748
Apotex Inc.	Apo-Abacavir-Lamivudine-Zidovudine	Trizivir	abacavir/lamivudine/zidovudine	300mg/ 150mg/ 300mg	FC tablet	02416255
Jamp Pharma Corporation	Jamp-Valacyclovir	Valtrex	valacyclovir HCl	500mg	FC tablet	02441454
Jamp Pharma Corporation	Jamp-Moxifloxacin	Avelox	moxifloxacin HCl	400mg	FC tablet	02443929
Marcan Pharmaceuticals Inc.	Mar-Valacyclovir	Valtrex	valacyclovir HCl	500mg	FC tablet	02441586

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Mint Pharmaceuticals Inc.	Mint-Citalopram	Celexa	citalopram	20mg	FC tablet	02429705
Mint Pharmaceuticals Inc.	Mint-Citalopram	Celexa	citalopram	40mg	FC tablet	02429713
Mylan Pharmaceuticals ULC	Mylan-Tolterodine ER	Detrol LA	tolterodine L-tartrate	2mg	ER capsule	02404184
Mylan Pharmaceuticals ULC	Mylan-Tolterodine ER	Detrol LA	tolterodine L-tartrate	4mg	ER capsule	02404192
Teva Canada Limited	Teva-Valacyclovir	Valtrex	valacyclovir HCl	500mg	FC tablet	02357534